Eli Lilly

U.S. pharma major behind Mounjaro and Zepbound — the biggest beneficiary of the obesity-drug boom.

Coverage of Eli Lilly is holding steady →: 4 signals on the latest tracked day, level with its three-week baseline of 4, across 3 domains. That makes it the #144 most-covered of the 173 concerns we track.

Eli Lilly is steady by its own history. Its normal rhythm is about 4 signals a day across 3 domains. A real move would be a day at 5+ signals — 25% above that baseline, the bar our trend read calls accelerating ↑ — or a spread into domains beyond its usual 3. That is the move that would push it up the Wire. It sits on our Health & Bio Desk.